What is the recommended treatment regimen for an 80-year-old male with superficial basal cell carcinoma of the forehead using Efudex (imiquimod)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Superficial Basal Cell Carcinoma on Forehead with Efudex in 80-Year-Old Male

Apply Efudex (5-fluorouracil) 5% cream twice daily to the lesion for 3-6 weeks, potentially extending to 10-12 weeks until complete obliteration, though you should strongly consider imiquimod as a superior alternative for this patient. 1

Critical Clarification: Efudex vs. Imiquimod

First, note that Efudex is 5-fluorouracil (5-FU), not imiquimod as suggested in your expanded question. These are distinct topical agents with different efficacy profiles for superficial BCC.

FDA-Approved Efudex Regimen

For superficial basal cell carcinoma specifically:

  • Use only the 5% strength formulation 1
  • Apply twice daily in sufficient amount to cover the lesion 1
  • Continue for minimum 3-6 weeks, but therapy may require 10-12 weeks before lesions are obliterated 1
  • Complete healing may take 1-2 months after stopping treatment 1
  • Apply with non-metal applicator or glove; wash hands immediately if using fingers 1

Expected response sequence: erythema → vesiculation → desquamation → erosion → re-epithelialization. Terminate when inflammatory response reaches erosion stage for actinic keratoses, but continue longer for BCC 1

Important Efficacy Consideration

Efudex has approximately 93% success rate for superficial BCC based on FDA label data 1, which is inferior to imiquimod's 80% tumor-free rate at 3 years 2. The 2018 AAD guidelines demonstrate that imiquimod is superior to 5-FU for superficial BCC, with 3-year tumor-free rates of 80% vs 68% respectively 2.

Why This Matters for Your 80-Year-Old Patient

For an elderly patient where surgery may be impractical or declined, topical therapy is appropriate 3. However:

  • Imiquimod shows better long-term efficacy than 5-FU for superficial BCC 2
  • Both are Level A recommendations with Level I evidence 2
  • 5-FU may be preferred if the patient cannot tolerate the inflammatory response from imiquimod, which can be more intense 2
  • Dose adjustments based on tolerance are reasonable - consider every-other-day treatment with treatment holidays if local reactions are severe 2

Critical Follow-Up Requirements

The patient must be followed for a reasonable period to determine if cure has been obtained 1. This is non-negotiable given the ~7% failure rate with 5-FU cream 1.

Common Pitfalls to Avoid

  • Do not use Efudex for nodular or aggressive BCC subtypes - only superficial BCC 1
  • Do not use on difficult anatomic sites where surgical success approaches 100% - surgery remains preferred for isolated, easily accessible lesions 1
  • Expect significant local skin reactions (erythema, swelling, erosions, crusts) that may limit compliance 2
  • Confirm diagnosis before treatment - this method has not been proven effective in other BCC types 1

Alternative Recommendation

Given the superior efficacy data, strongly consider switching to imiquimod 5% cream applied 5 times weekly for 6 weeks, which achieves 84-90% initial clearance rates 3, 4 and better long-term outcomes than 5-FU 2. For elderly patients specifically, imiquimod has shown 67% clinical remission at 10 weeks and 49.5% at 1 year in patients >65 years 5.

References

Guideline

guidelines of care for the management of basal cell carcinoma.

Journal of the American Academy of Dermatology, 2018

Guideline

basal cell skin cancer, version 1.2016, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

Research

Imiquimod: in superficial basal cell carcinoma.

American journal of clinical dermatology, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.